antibodies, monoclonal, humanized

Preferred Label : antibodies, monoclonal, humanized;

MeSH definition : Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.;

MeSH synonym : antibodies, humanized; humanized antibodies;

Wikipedia link : https://en.wikipedia.org/wiki/Humanized antibodies;

Is substance : O;

Details

Origin ID

D061067;

UMLS CUI

C2985546;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- Humanized Monoclonal Antibody [NCIt concept]
Indexing information
- K7153A [MeSH Supplementary Concept]
Record concept(s)
- antibodies, monoclonal, humanized [MeSH concept]
Related MeSH Supplementary Concept(s)
- (111In-DTPA)n-trastuzumab-(IRDye800)m [MeSH Supplementary Concept]
- 111In-DTPA-trastuzumab [MeSH Supplementary Concept]
- 188Re-SOCTA-trastuzumab [MeSH Supplementary Concept]
- 1D09C3 monoclonal antibody [MeSH Supplementary Concept]
- 3BNC117 antibody [MeSH Supplementary Concept]
- 64Cu-DOTA-trastuzumab [MeSH Supplementary Concept]
- 8-1A monoclonal antibody, human [MeSH Supplementary Concept]
- 89Zr-bevacizumab [MeSH Supplementary Concept]
- 99mTc-hR3 monoclonal antibody [MeSH Supplementary Concept]
- A1mcMMAF [MeSH Supplementary Concept]
- AB023 [MeSH Supplementary Concept]
- ABI793 monoclonal antibody [MeSH Supplementary Concept]
- ABT-414 [MeSH Supplementary Concept]
- ABX-Interleukin 8 [MeSH Supplementary Concept]
- AGS-16C3F [MeSH Supplementary Concept]
- AGS67E [MeSH Supplementary Concept]
- AK002 [MeSH Supplementary Concept]
- ALD1613 monoclonal antibody [MeSH Supplementary Concept]
- ALD518 monoclonal antibody [MeSH Supplementary Concept]
- ALXN4100 [MeSH Supplementary Concept]
- ALXN4100TPO [MeSH Supplementary Concept]
- AMG 139 [MeSH Supplementary Concept]
- AMG 317 [MeSH Supplementary Concept]
- AMG 557 [MeSH Supplementary Concept]
- AMG 811 [MeSH Supplementary Concept]
- AMG-714 [MeSH Supplementary Concept]
- ASK8007 monoclonal antibody [MeSH Supplementary Concept]
- ASN100 [MeSH Supplementary Concept]
- ATR-107 [MeSH Supplementary Concept]
- AV-203 [MeSH Supplementary Concept]
- AVE1642 [MeSH Supplementary Concept]
- AVE9633 [MeSH Supplementary Concept]
- AVP-21D9 [MeSH Supplementary Concept]
- Abituzumab [MeSH Supplementary Concept]
- BHQ880 [MeSH Supplementary Concept]
- BI 655064 [MeSH Supplementary Concept]
- BI 836826 [MeSH Supplementary Concept]
- BI 836858 [MeSH Supplementary Concept]
- BIIB022 [MeSH Supplementary Concept]
- BIIB023 [MeSH Supplementary Concept]
- BIIB036 [MeSH Supplementary Concept]
- BIW-8962 [MeSH Supplementary Concept]
- BMS-936559 [MeSH Supplementary Concept]
- BT-061 [MeSH Supplementary Concept]
- CIS43LS [MeSH Supplementary Concept]
- CNTO 5825 [MeSH Supplementary Concept]
- CNTO6785 [MeSH Supplementary Concept]
- COU-1 antibody [MeSH Supplementary Concept]
- CPI-006 [MeSH Supplementary Concept]
- CR002 [MeSH Supplementary Concept]
- CS-1003 [MeSH Supplementary Concept]
- CT-P17 [MeSH Supplementary Concept]
- CX-2029 [MeSH Supplementary Concept]
- DHES0815A [MeSH Supplementary Concept]
- DS-5573a [MeSH Supplementary Concept]
- DS-8273a [MeSH Supplementary Concept]
- DX-2400 [MeSH Supplementary Concept]
- EG-19-11 [MeSH Supplementary Concept]
- F8 monoclonal antibody [MeSH Supplementary Concept]
- FK734 monoclonal antibody [MeSH Supplementary Concept]
- FR255734 [MeSH Supplementary Concept]
- Fletikumab [MeSH Supplementary Concept]
- GC1118 [MeSH Supplementary Concept]
- GMA-161 [MeSH Supplementary Concept]
- GSK1070806 [MeSH Supplementary Concept]
- GSK1995057 [MeSH Supplementary Concept]
- GSK2618960 [MeSH Supplementary Concept]
- GSK2849330 [MeSH Supplementary Concept]
- GSK3050002 [MeSH Supplementary Concept]
- GSK315234 [MeSH Supplementary Concept]
- GSK679586 [MeSH Supplementary Concept]
- HBM9161 [MeSH Supplementary Concept]
- HLX07 [MeSH Supplementary Concept]
- HLX70 antibody [MeSH Supplementary Concept]
- HMMC-1 monoclonal antibody [MeSH Supplementary Concept]
- Hu-P4G7 antibody [MeSH Supplementary Concept]
- Hu14.18K322A monoclonal antibody [MeSH Supplementary Concept]
- Hu3S193 monoclonal antibody [MeSH Supplementary Concept]
- HuMax-IL8 [MeSH Supplementary Concept]
- IBIO123 [MeSH Supplementary Concept]
- IC100 monoclonal antibody [MeSH Supplementary Concept]
- IMC-001 [MeSH Supplementary Concept]
- IMMU-110 [MeSH Supplementary Concept]
- IMMU-114 [MeSH Supplementary Concept]
- IPH-2101 [MeSH Supplementary Concept]
- Icrucumab [MeSH Supplementary Concept]
- Istiratumab [MeSH Supplementary Concept]
- JNJ-55920839 [MeSH Supplementary Concept]
- JTA-009 [MeSH Supplementary Concept]
- KHK4083 [MeSH Supplementary Concept]
- KRN-330 [MeSH Supplementary Concept]
- L612 monoclonal antibody [MeSH Supplementary Concept]
- LDP-02 [MeSH Supplementary Concept]
- LFA102 monoclonal antibody [MeSH Supplementary Concept]
- LFB-R593 [MeSH Supplementary Concept]
- LY2189102 [MeSH Supplementary Concept]
- LY2624587 [MeSH Supplementary Concept]
- LY2787106 [MeSH Supplementary Concept]
- LY3076226 [MeSH Supplementary Concept]
- LY3321367 [MeSH Supplementary Concept]
- Lerdelimumab [MeSH Supplementary Concept]
- MAA868 [MeSH Supplementary Concept]
- MDX-1100 [MeSH Supplementary Concept]
- MDX-1401 [MeSH Supplementary Concept]
- MDX-H210 antibody [MeSH Supplementary Concept]
- MED18852 [MeSH Supplementary Concept]
- MEDI-5304 [MeSH Supplementary Concept]
- MEDI-570 [MeSH Supplementary Concept]
- MEDI2070 [MeSH Supplementary Concept]
- MEDI3617 [MeSH Supplementary Concept]
- MK-4166 [MeSH Supplementary Concept]
- MK-4721 [MeSH Supplementary Concept]
- MLN02 antibody, human [MeSH Supplementary Concept]
- MM-151 [MeSH Supplementary Concept]
- MORAb-202 [MeSH Supplementary Concept]
- MV833 monoclonal antibody, human [MeSH Supplementary Concept]
- MW06 mAb [MeSH Supplementary Concept]
- NI-0101 [MeSH Supplementary Concept]
- NKTT120 [MeSH Supplementary Concept]
- NNC0215-0384 [MeSH Supplementary Concept]
- Otilimab [MeSH Supplementary Concept]
- PF-03475952 [MeSH Supplementary Concept]
- PF-03732010 monoclonal antibody [MeSH Supplementary Concept]
- PF-04236921 [MeSH Supplementary Concept]
- PF-04605412 [MeSH Supplementary Concept]
- PF-05231023 [MeSH Supplementary Concept]
- PF-05280014 [MeSH Supplementary Concept]
- PF-06263507 [MeSH Supplementary Concept]
- PF-06650808 [MeSH Supplementary Concept]
- PRO70769 monoclonal antibody [MeSH Supplementary Concept]
- PSMA ADC [MeSH Supplementary Concept]
- PankoMab-GEX [MeSH Supplementary Concept]
- RC48 antibody [MeSH Supplementary Concept]
- REGN14256 [MeSH Supplementary Concept]
- RG7212 [MeSH Supplementary Concept]
- RG7356 [MeSH Supplementary Concept]
- RG7652 [MeSH Supplementary Concept]
- RN909 [MeSH Supplementary Concept]
- RSHZ19 monoclonal antibody [MeSH Supplementary Concept]
- S2X259 [MeSH Supplementary Concept]
- SAIT301 [MeSH Supplementary Concept]
- SAR-566658 [MeSH Supplementary Concept]
- SAR252067 [MeSH Supplementary Concept]
- SC-1 monoclonal antibody [MeSH Supplementary Concept]
- SGN-75 antibody-drug conjugate [MeSH Supplementary Concept]
- SP1-77 antibody [MeSH Supplementary Concept]
- SRK-181 [MeSH Supplementary Concept]
- TB 402 [MeSH Supplementary Concept]
- TB-403 [MeSH Supplementary Concept]
- TGN-1412 [MeSH Supplementary Concept]
- TI-23 human monoclonal antibody [MeSH Supplementary Concept]
- TNT009 [MeSH Supplementary Concept]
- TONO-1 monoclonal antibody [MeSH Supplementary Concept]
- TRL1068 [MeSH Supplementary Concept]
- TRX-4 monoclonal antibody [MeSH Supplementary Concept]
- TSR-033 [MeSH Supplementary Concept]
- TUB-OH-trastuzumab [MeSH Supplementary Concept]
- TUB-OMOM-trastuzumab [MeSH Supplementary Concept]
- TY014 [MeSH Supplementary Concept]
- TheraCIM [MeSH Supplementary Concept]
- Tovetumab [MeSH Supplementary Concept]
- U3-1565 [MeSH Supplementary Concept]
- UB-421 [MeSH Supplementary Concept]
- VIS410 monoclonal antibody [MeSH Supplementary Concept]
- VX15-2503 monoclonal antibody [MeSH Supplementary Concept]
- XMAB-2513 [MeSH Supplementary Concept]
- XOMA 358 [MeSH Supplementary Concept]
- abelacimab [MeSH Supplementary Concept]
- abrilumab [MeSH Supplementary Concept]
- adecatumumab [MeSH Supplementary Concept]
- aducanumab [MeSH Supplementary Concept]
- alirocumab [MeSH Supplementary Concept]
- amubarvimab [MeSH Supplementary Concept]
- andecaliximab [MeSH Supplementary Concept]
- anifrolumab [MeSH Supplementary Concept]
- anrukinzumab [MeSH Supplementary Concept]
- ansuvimab [MeSH Supplementary Concept]
- apitegromab [MeSH Supplementary Concept]
- apolizumab [MeSH Supplementary Concept]
- aprutumab ixadotin [MeSH Supplementary Concept]
- ascrinvacumab [MeSH Supplementary Concept]
- astegolimab [MeSH Supplementary Concept]
- atezolizumab [MeSH Supplementary Concept]
- atoltivimab [MeSH Supplementary Concept]
- atoltivimab, maftivimab, and odesivimab-ebgn drug combination [MeSH Supplementary Concept]
- avdoralimab [MeSH Supplementary Concept]
- avelumab [MeSH Supplementary Concept]
- axatilimab [MeSH Supplementary Concept]
- balstilimab [MeSH Supplementary Concept]
- bamlanivimab [MeSH Supplementary Concept]
- bapineuzumab [MeSH Supplementary Concept]
- belantamab mafodotin [MeSH Supplementary Concept]
- belimumab [MeSH Supplementary Concept]
- bemarituzumab [MeSH Supplementary Concept]
- benralizumab [MeSH Supplementary Concept]
- bermekimab [MeSH Supplementary Concept]
- bexmarilimab [MeSH Supplementary Concept]
- bimagrumab [MeSH Supplementary Concept]
- bimekizumab [MeSH Supplementary Concept]
- birtamimab [MeSH Supplementary Concept]
- bivatuzumab mertansine [MeSH Supplementary Concept]
- bleselumab [MeSH Supplementary Concept]
- blosozumab [MeSH Supplementary Concept]
- bococizumab [MeSH Supplementary Concept]
- briakinumab [MeSH Supplementary Concept]
- brodalumab [MeSH Supplementary Concept]
- brolucizumab [MeSH Supplementary Concept]
- bromoacetyl-TMT [MeSH Supplementary Concept]
- budigalimab [MeSH Supplementary Concept]
- burosumab [MeSH Supplementary Concept]
- byooviz [MeSH Supplementary Concept]
- cairalizmab [MeSH Supplementary Concept]
- camrelizumab [MeSH Supplementary Concept]
- canakinumab [MeSH Supplementary Concept]
- cantuzumab mertansine [MeSH Supplementary Concept]
- carlumab [MeSH Supplementary Concept]
- casirivimab [MeSH Supplementary Concept]
- casirivimab and imdevimab drug combination [MeSH Supplementary Concept]
- cemiplimab [MeSH Supplementary Concept]
- cirmtuzumab [MeSH Supplementary Concept]
- cixutumumab [MeSH Supplementary Concept]
- clazakizumab [MeSH Supplementary Concept]
- codrituzumab [MeSH Supplementary Concept]
- cofetuzumab pelidotin [MeSH Supplementary Concept]
- coltuximab ravtansine [MeSH Supplementary Concept]
- concizumab [MeSH Supplementary Concept]
- crenezumab [MeSH Supplementary Concept]
- crexavibart [MeSH Supplementary Concept]
- crizanlizumab [MeSH Supplementary Concept]
- crotedumab [MeSH Supplementary Concept]
- dacetuzumab [MeSH Supplementary Concept]
- daclizumab HYP [MeSH Supplementary Concept]
- dalotuzumab [MeSH Supplementary Concept]
- demcizumab [MeSH Supplementary Concept]
- depatuxizumab [MeSH Supplementary Concept]
- depatuxizumab mafodotin [MeSH Supplementary Concept]
- domagrozumab [MeSH Supplementary Concept]
- donanemab [MeSH Supplementary Concept]
- dostarlimab [MeSH Supplementary Concept]
- drozitumab [MeSH Supplementary Concept]
- dupilumab [MeSH Supplementary Concept]
- dusigitumab [MeSH Supplementary Concept]
- ecromeximab [MeSH Supplementary Concept]
- eculizumab [MeSH Supplementary Concept]
- efalizumab [MeSH Supplementary Concept]
- efgartigimod alfa [MeSH Supplementary Concept]
- efungumab [MeSH Supplementary Concept]
- elezanumab [MeSH Supplementary Concept]
- elotuzumab [MeSH Supplementary Concept]
- emactuzumab [MeSH Supplementary Concept]
- emibetuzumab [MeSH Supplementary Concept]
- emicizumab [MeSH Supplementary Concept]
- enavatuzumab [MeSH Supplementary Concept]
- enibarcimab [MeSH Supplementary Concept]
- enokizumab [MeSH Supplementary Concept]
- enoticumab [MeSH Supplementary Concept]
- enuzovimab [MeSH Supplementary Concept]
- envafolimab [MeSH Supplementary Concept]
- epitumomab [MeSH Supplementary Concept]
- epratuzumab [MeSH Supplementary Concept]
- eptinezumab [MeSH Supplementary Concept]
- erenumab [MeSH Supplementary Concept]
- etaracizumab [MeSH Supplementary Concept]
- etesevimab [MeSH Supplementary Concept]
- etrolizumab [MeSH Supplementary Concept]
- evolocumab [MeSH Supplementary Concept]
- farletuzumab [MeSH Supplementary Concept]
- fasinumab [MeSH Supplementary Concept]
- felzartamab [MeSH Supplementary Concept]
- fezakinumab [MeSH Supplementary Concept]
- firategrast [MeSH Supplementary Concept]
- fontolizumab [MeSH Supplementary Concept]
- fresolimumab [MeSH Supplementary Concept]
- fulranumab [MeSH Supplementary Concept]
- galcanezumab [MeSH Supplementary Concept]
- ganitumab [MeSH Supplementary Concept]
- gantenerumab [MeSH Supplementary Concept]
- gedivumab [MeSH Supplementary Concept]
- gevokizumab [MeSH Supplementary Concept]
- gimsilumab [MeSH Supplementary Concept]
- glenzocimab [MeSH Supplementary Concept]
- gm4 antibody [MeSH Supplementary Concept]
- gosuranemab [MeSH Supplementary Concept]
- guselkumab [MeSH Supplementary Concept]
- herceptin-rhodamine green conjugate [MeSH Supplementary Concept]
- hersintuzumab [MeSH Supplementary Concept]
- hu5C8 antibody [MeSH Supplementary Concept]
- humanized 3F8 anti-GD2 monoclonal antibody [MeSH Supplementary Concept]
- ianalumab [MeSH Supplementary Concept]
- ichorcumab [MeSH Supplementary Concept]
- idarucizumab [MeSH Supplementary Concept]
- imdevimab [MeSH Supplementary Concept]
- imgatuzumab [MeSH Supplementary Concept]
- indusatumab [MeSH Supplementary Concept]
- inebilizumab [MeSH Supplementary Concept]
- intetumumab [MeSH Supplementary Concept]
- isatuximab [MeSH Supplementary Concept]
- itepekimab [MeSH Supplementary Concept]
- itolizumab [MeSH Supplementary Concept]
- ixekizumab [MeSH Supplementary Concept]
- labetuzumab [MeSH Supplementary Concept]
- labetuzumab govitecan [MeSH Supplementary Concept]
- lanadelumab [MeSH Supplementary Concept]
- landogrozumab [MeSH Supplementary Concept]
- lecanemab [MeSH Supplementary Concept]
- lenzilumab [MeSH Supplementary Concept]
- leronlimab [MeSH Supplementary Concept]
- lesofavumab [MeSH Supplementary Concept]
- levilimab [MeSH Supplementary Concept]
- lifastuzumab vedotin [MeSH Supplementary Concept]
- ligelizumab [MeSH Supplementary Concept]
- lintuzumab [MeSH Supplementary Concept]
- loncastuximab tesirine [MeSH Supplementary Concept]
- lucatumumab [MeSH Supplementary Concept]
- lumretuzumab [MeSH Supplementary Concept]
- m708.5 monoclonal antibody [MeSH Supplementary Concept]
- maftivimab [MeSH Supplementary Concept]
- magrolimab [MeSH Supplementary Concept]
- mapatumumab [MeSH Supplementary Concept]
- marstacimab [MeSH Supplementary Concept]
- matuzumab [MeSH Supplementary Concept]
- mavrilimumab [MeSH Supplementary Concept]
- melrilimab [MeSH Supplementary Concept]
- meplazumab [MeSH Supplementary Concept]
- mepolizumab [MeSH Supplementary Concept]
- milatuzumab [MeSH Supplementary Concept]
- mirikizumab [MeSH Supplementary Concept]
- mirvetuximab soravtansine [MeSH Supplementary Concept]
- mitazalimab [MeSH Supplementary Concept]
- mogamulizumab [MeSH Supplementary Concept]
- monalizumab [MeSH Supplementary Concept]
- monoclonal antibody 9E4 [MeSH Supplementary Concept]
- monoclonal antibody BIWA 4 [MeSH Supplementary Concept]
- monoclonal antibody RN168 [MeSH Supplementary Concept]
- monoclonal antibody YYB-101 [MeSH Supplementary Concept]
- motavizumab [MeSH Supplementary Concept]
- namilumab [MeSH Supplementary Concept]
- naratuximab emtansine [MeSH Supplementary Concept]
- narsoplimab [MeSH Supplementary Concept]
- naxitamab-gqgk [MeSH Supplementary Concept]
- nebacumab [MeSH Supplementary Concept]
- necitumumab [MeSH Supplementary Concept]
- nemolizumab [MeSH Supplementary Concept]
- netakimab [MeSH Supplementary Concept]
- nimotuzumab [MeSH Supplementary Concept]
- nirsevimab [MeSH Supplementary Concept]
- obinutuzumab [MeSH Supplementary Concept]
- ocaratuzumab [MeSH Supplementary Concept]
- ocrelizumab [MeSH Supplementary Concept]
- odesivimab [MeSH Supplementary Concept]
- ofatumumab [MeSH Supplementary Concept]
- ogalvibart [MeSH Supplementary Concept]
- ogalvibart, crexavibart drug combination [MeSH Supplementary Concept]
- olinvacimab [MeSH Supplementary Concept]
- olokizumab [MeSH Supplementary Concept]
- ontamalimab [MeSH Supplementary Concept]
- ontuxizumab [MeSH Supplementary Concept]
- orilanolimab [MeSH Supplementary Concept]
- osocimab [MeSH Supplementary Concept]
- otelixizumab [MeSH Supplementary Concept]
- ozanezumab [MeSH Supplementary Concept]
- pamrevlumab [MeSH Supplementary Concept]
- parsatuzumab [MeSH Supplementary Concept]
- pateclizumab [MeSH Supplementary Concept]
- patritumab [MeSH Supplementary Concept]
- patritumab deruxtecan [MeSH Supplementary Concept]
- pembrolizumab [MeSH Supplementary Concept]
- penpulimab [MeSH Supplementary Concept]
- pepinemab [MeSH Supplementary Concept]
- pertuzumab [MeSH Supplementary Concept]
- pexelizumab [MeSH Supplementary Concept]
- pinatuzumab vedotin [MeSH Supplementary Concept]
- plonmarlimab [MeSH Supplementary Concept]
- plozalizumab [MeSH Supplementary Concept]
- ponezumab [MeSH Supplementary Concept]
- procizumab [MeSH Supplementary Concept]
- quetmolimab [MeSH Supplementary Concept]
- ravulizumab [MeSH Supplementary Concept]
- raxibacumab [MeSH Supplementary Concept]
- refanezumab [MeSH Supplementary Concept]
- regdanvimab [MeSH Supplementary Concept]
- relatlimab [MeSH Supplementary Concept]
- reslizumab [MeSH Supplementary Concept]
- rhuMAb2H7 [MeSH Supplementary Concept]
- rilotumumab [MeSH Supplementary Concept]
- robatumumab [MeSH Supplementary Concept]
- romlusevimab [MeSH Supplementary Concept]
- rontalizumab [MeSH Supplementary Concept]
- rovalpituzumab tesirine [MeSH Supplementary Concept]
- rovelizumab [MeSH Supplementary Concept]
- rozanolixizumab [MeSH Supplementary Concept]
- sacituzumab govitecan [MeSH Supplementary Concept]
- samalizumab [MeSH Supplementary Concept]
- sarilumab [MeSH Supplementary Concept]
- satralizumab [MeSH Supplementary Concept]
- secukinumab [MeSH Supplementary Concept]
- selicrelumab [MeSH Supplementary Concept]
- seribantumab [MeSH Supplementary Concept]
- serrumab [MeSH Supplementary Concept]
- sibrotuzumab [MeSH Supplementary Concept]
- sifalimumab [MeSH Supplementary Concept]
- simtuzumab [MeSH Supplementary Concept]
- sintilimab [MeSH Supplementary Concept]
- siplizumab [MeSH Supplementary Concept]
- sirtratumab vedotin [MeSH Supplementary Concept]
- sirukumab [MeSH Supplementary Concept]
- solanezumab [MeSH Supplementary Concept]
- sotrovimab [MeSH Supplementary Concept]
- spartalizumab [MeSH Supplementary Concept]
- spesolimab [MeSH Supplementary Concept]
- sugemalimab [MeSH Supplementary Concept]
- sutimlimab [MeSH Supplementary Concept]
- suvratoxumab [MeSH Supplementary Concept]
- tabalumab [MeSH Supplementary Concept]
- tafasitamab [MeSH Supplementary Concept]
- talizumab [MeSH Supplementary Concept]
- tanezumab [MeSH Supplementary Concept]
- technetium 99m HYNIC-tocilizumab [MeSH Supplementary Concept]
- technetium 99m tricarbonyl bevacizumab [MeSH Supplementary Concept]
- temelimab [MeSH Supplementary Concept]
- teplizumab [MeSH Supplementary Concept]
- teprotumumab [MeSH Supplementary Concept]
- tesidolumab [MeSH Supplementary Concept]
- tezepelumab [MeSH Supplementary Concept]
- thorium-227-p-isothiocyanato-benzyl-DOTA-trastuzumab [MeSH Supplementary Concept]
- thorium-227DOTA-p-benzyl-trastuzumab [MeSH Supplementary Concept]
- thromboview [MeSH Supplementary Concept]
- tigatuzumab [MeSH Supplementary Concept]
- tilavonemab [MeSH Supplementary Concept]
- tildrakizumab [MeSH Supplementary Concept]
- tislelizumab [MeSH Supplementary Concept]
- tisotumab vedotin [MeSH Supplementary Concept]
- tocilizumab [MeSH Supplementary Concept]
- tomaralimab [MeSH Supplementary Concept]
- toralizumab [MeSH Supplementary Concept]
- toripalimab [MeSH Supplementary Concept]
- trastuzumab deruxtecan [MeSH Supplementary Concept]
- tregalizumab [MeSH Supplementary Concept]
- tremelimumab [MeSH Supplementary Concept]
- ulocuplumab [MeSH Supplementary Concept]
- upanovimab [MeSH Supplementary Concept]
- urtoxazumab [MeSH Supplementary Concept]
- utomilumab [MeSH Supplementary Concept]
- vadastuximab talirine [MeSH Supplementary Concept]
- vanucizumab [MeSH Supplementary Concept]
- varlilumab [MeSH Supplementary Concept]
- vedolizumab [MeSH Supplementary Concept]
- veltuzumab [MeSH Supplementary Concept]
- visilizumab [MeSH Supplementary Concept]
- vofatamab [MeSH Supplementary Concept]
- volagidemab [MeSH Supplementary Concept]
- xentuzumab [MeSH Supplementary Concept]
- zalutumumab [MeSH Supplementary Concept]
- zanolimumab [MeSH Supplementary Concept]
- zansecimab [MeSH Supplementary Concept]
- zaptuzumab [MeSH Supplementary Concept]
- ziltivekimab [MeSH Supplementary Concept]
- zimberelimab [MeSH Supplementary Concept]
- zirconium-89-trastuzumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
UMLS correspondences (same concept)
- Humanized Monoclonal Antibody [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients